Yorvipath (palopegteriparatide) has been approved in Australia as a parathyroid hormone (PTH) replacement therapy for adults with chronic…
Andrea Lobo
Andrea Lobo is a Science writer at BioNews. She holds a Biology degree and a PhD in Cell Biology/Neurosciences from the University of Coimbra-Portugal, where she studied stroke biology. She was a postdoctoral and senior researcher at the Institute for Research and Innovation in Health in Porto, in drug addiction, studying neuronal plasticity induced by amphetamines. As a research scientist for 19 years, Andrea participated in academic projects in multiple research fields, from stroke, gene regulation, cancer, and rare diseases. She authored multiple research papers in peer-reviewed journals. She shifted towards a career in science writing and communication in 2022.
At Bionews we’re committed to providing the most accurate, relevant, and up-to-date reporting for our patient communities. Our goal is to ensure that everyone has access to disease-specific information that is both trustworthy and easy to understand. You can read more about our editorial policy here.
Articles by Andrea Lobo
Slightly less than 20% of people who had their thyroid gland removed had hypoparathyroidism a year after the surgery,…
People with hypoparathyroidism experience worse quality of life, with women showing a higher burden of disease than men, according…
People with autoimmune hypoparathyroidism who have anti-CaSR antibodies — which play a role in regulating the parathyroid hormone, known as…
Two severe cases of hypoparathyroidism were associated with two newly identified mutations in the glial cell missing homolog 2 (GCM2)…
Treatment with radioiodine extended the recovery of parathyroid function in patients who underwent surgical thyroid removal, in some cases beyond…